cadonilimab
akesobio
['ak104', 'cadonilimab', 'akeso']
akeso announced oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022. click the link to find more details: 
We are dedicated to the research, development, manufacturing and commercialization of novel antibody drugs that are affordable to patients worldwide.
#9926.HK